APUS — Apimeds Pharmaceuticals US, Inc.
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 1894525 ·
Last close
$1.95
Market Cap
$2.94M
52W High
$59.70
52W Low
$1.51
ADV30
1,001,588
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 2,898,899 | 2,844,599 | 2,030,122 | 33,646,166 | 153,530,115 | 17,912 | 13,007,142 |
| Jun 2026 | 0 | — | -6,278,760 | -20,173,129 | 127,623,697 | 278,371 | 21,175,156 |
| Mar 2026 | 0 | — | -12,185,694 | -35,059,852 | 141,219,157 | 979,534 | 14,703,698 |
| Dec 2025 | 0 | — | -7,040,051 | -1,155,292 | 164,183,736 | 1,636,655 | 10,835,909 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-13,279,260
Investing CF
$-8,056,376
Financing CF
$12,878,683
CapEx
$-53,358
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-38.34
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-65,626,043
Inventory
—
Receivables
$131,251
ST Investments
$0
EBIT TTM
$-53,864,443
Pretax Income TTM
$-58,169,528
Interest Exp TTM
$4,305,085
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -11,912,562 | -6,001,137 | 164,183,736 | 10,835,909 | 153,347,827 | -8,925,777 |
| Dec 2024 | 0 | -1,275,095 | -1,389,990 | 13,057 | 1,371,178 | -1,358,121 | -733,526 |
| Dec 2023 | 0 | -747,436 | -777,694 | 422,076 | 390,207 | 31,869 | -627,790 |
| Dec 2022 | 0 | -639,529 | -668,666 | 6,171 | 719,777 | -713,606 | -448,167 |
TTM Snapshot
Revenues TTM
$114,116
NetIncome TTM
$-58,169,528
OpCashFlow TTM
—
Assets (Latest)
$127,623,697
Forward EPS
—
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| GRI | GRI Bio, Inc. | $2.95M | $1.35 | — |
| MDCX | Medicus Pharma Ltd. | $2.89M | $1.52 | — |
| GELS | Gelteq Ltd | $2.88M | $0.27 | — |
| NRSN | NeuroSense Therapeutics Ltd. | $2.86M | $1.51 | — |
| DRMA | Dermata Therapeutics, Inc. | $2.81M | $0.57 | — |
News headlines (Yahoo Finance, 1h cache)
Apimeds Pharmaceuticals US Reports Third Quarter 2026 Results, Delivers First Operating Revenue from Technology Services
2026-11-18 13:44 · Yahoo
Why Is Apimeds Pharmaceuticals Stock Gaining Monday?
2026-10-05 14:08 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.